In addition to the effectiveness of aripiprazole monotherapy for schizophrenia [29,30], its mechanism of action (partial agonist/modulator at D2 receptors) makes it useful in normalizing serum prolactin levels when combined with other antipsychotics [31]. This evidence concerns the gene PRL and schizophrenia.